
Sign up to save your podcasts
Or


These days, many laboratories are eager to apply AI, but the systems and workflows that they have implemented often stand in the way. When systems run separately, information gets trapped in silos and scientific context is lost between steps. Also, manual handoffs slow the work down and introduce risk at various points in lab processes. Connecting those systems and workflows first gives AI the operational and scientific context it needs to deliver value that can be both trusted and scaled.
In this GEN podcast, the third in a series, LabVantage’s Denise Bell discusses how laboratories can reduce operational fragmentation and build connected, scalable operations. The discussion covers workflow orchestration across laboratory functions, ways to reduce manual handoffs and information silos, and offers some practical starting points for AI adoption. It also looks at how bringing LIMS, ELN, LES, and SDMS together in a unified laboratory execution environment enables workflow intelligence and AI assistance in the right scientific and operational context.
Speaker: Denise Bell
Moderator: Uduak Thomas
Hosted on Acast. See acast.com/privacy for more information.
Episode 1: Precision Automation Meets Biology
Central question: How can automation help scientists move faster without losing sight of the biology?
This opening episode would introduce precision automation as the connective tissue across the Molecular Devices portfolio. Rather than defining automation simply as higher throughput, we would explore how purpose-built tools help biologists reduce repetitive work, control variability, improve consistency, and focus more of their time on scientific decisions.
Potential discussion points:
Speaker: Matt Stoltz
Moderator: Uduak Thomas
Hosted on Acast. See acast.com/privacy for more information.
Artificial intelligence is advancing quickly into laboratory operations, which is why thinking about the quality and integrity of the supporting data early on is important. In regulated environments, that means understanding where the data came from, how it changes, and how AI-generated insights or recommendations can be traced, reviewed, trusted, and ultimately defended.
In this GEN podcast, LabVantage’s Gary Stimson digs into what it takes to build a data foundation for trustworthy AI. The discussion covers concepts like data lineage, traceability, explainability and governance, and the importance of audit-ready laboratory operations. It also looks at the role of intended use, ongoing monitoring, and human review in deploying AI responsibly.
Hosted on Acast. See acast.com/privacy for more information.
Small molecules continue to play a major part in pharmaceutical development, but increasing molecular complexity, accelerated timelines, and evolving manufacturing and regulatory requirements are creating new challenges for the industry.
In this GEN Podcast – part 2 in a 3-part series -- a trio of experts from SK Pharmteco discuss how CDMOs are helping biopharma companies navigate critical areas including scale-up, technology transfer, advanced manufacturing, automation, sustainability, the emergence of AI, and supply chain reliability. The discussion explores practical strategies for improving development efficiency while supporting quality, scalability, and long-term commercial success.
Guest Speakers
Steve Barr, PhD -- Head of Small Molecule Business Unit and VP Global Alliances, SK Pharmteco.
Darryl Ratty -- Executive Director of Global ESG (Environmental, Social and Governance), SK Pharmteco.
Bill Dubay -- VP, Global Research and Development, SK Pharmteco.
Moderator:
Kevin Davies, PhD, Editorial Director, GEN
Hosted on Acast. See acast.com/privacy for more information.
This episode establishes the broader context for AI adoption. Rather than focusing on AI tools themselves, the discussion explores what laboratories must have in place before AI can be applied responsibly.
Key discussion areas include:
Relevant reference to LabVantage CORTEX:
LabVantage CORTEX embeds AI within laboratory execution workflows so that intelligence operates within existing scientific and compliance processes, rather than as an external layer.
Hosted on Acast. See acast.com/privacy for more information.
Lentiviral vectors are gaining momentum not just as ex vivo tools but as potential in vivo therapeutic platforms. But with that shift comes a number of manufacturing challenges, including higher doses, tighter control of impurities, greater batch consistency, and scalable processes to meet both clinical and commercial needs.
In this GEN Podcast, two experts from SK Pharmteco, a global CMO, address these challenges and lay out some best practices that guide the manufacture of lentiviral vectors with the requisite purity, robustness, and economic feasibility required for widespread clinical adoption.
Guest speakers:
Mardhani Aparajithan, Director of Manufacturing, Science and Technology, SK Pharmteco
Tatiana Nanda, PhD, CTO, Cell and Gene Therapy, SK Pharmteco
Moderator:
Kevin Davies, PhD, Editorial Director, GEN
Hosted on Acast. See acast.com/privacy for more information.
Sponsored by Seqera
As data volumes in life sciences continue to grow, bioinformaticians and researchers are more dependent than ever on solutions that help them streamline workflows, manage data, and scale their research. In this timely podcast, Evan Floden, CEO and co-founder of Seqera, shares how his company is addressing these needs through Nextflow—the open-source orchestrator for scalable, reproducible, and portable scientific workflows—and Seqera Platform, a unified solution for the entire scientific data lifecycle. He also discusses how Seqera has become a widely adopted solution, trusted by 13 of the top 20 pharmaceutical companies, empowering breakthroughs in drug discovery, genomics, clinical research, and.beyond.
Hosted on Acast. See acast.com/privacy for more information.
Hosted on Acast. See acast.com/privacy for more information.
Hosted on Acast. See acast.com/privacy for more information.
In this episode, you’ll hear a group of experts discussing base editing and how the technology is helping scientists engineer powerful cell therapies for various diseases including novel CAR-T therapies and hypoimmunogenic induced pluripotent stem cells. During the discussion, they will cover the merits of the Pin-point base editing platform, which introduces gene modifications without relying on double-strand DNA breaks, as well as how TotalSeq reagents, which confirm the safety and efficiency of editing with the Pin-point platform, support single cell multiomics analysis of edited cells.
Hosted on Acast. See acast.com/privacy for more information.
From the publisher's feed
Genetic Engineering & Biotechnology News (GEN) has retained its position as the premier biotech publication since its launch in 1981. GEN publishes a print edition monthly and has additional…
GEN's print magazine, which also can easily be accessed online, includes feature articles on emerging technologies, product roundups, in-depth overviews from key scientific and bioindustry meetings, and industry-standard tutorials and technical articles on drug discovery, bioprocessing, and assay technologies.
Hosted on Acast. See acast.com/privacy for more information.